Compare
AbbVie vs Cytokinetics (ABBV vs CYTK)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Cytokinetics (CYTK) -9.3%; so far this year the figures are +27.5% and -15.5%.
AbbVie is the larger company by market value, about 68.8 times the size of Cytokinetics.
Revenue grew +10.7% at ABBV and +29.9% at CYTK over the last year.
ABBV yields 2.38%. CYTK pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | CYTK | |
|---|---|---|
| Price | $291.31 | $53.69 |
| 1-day | +1.07% | -3.35% |
| YTD | +27.49% | -15.50% |
| 1 year | +34.39% | -9.29% |
| 3 years | +104.47% | +52.96% |
| Market cap | $514.9B | $7.5B |
| P/E | 50.1 | — |
| P/S | 7.80 | 66.02 |
| P/B | — | — |
| Revenue growth | +10.70% | +29.90% |
| EPS growth | +340.20% | — |
| Gross margin % | 73.7 | — |
| Net margin % | 15.7 | -686.6 |
| ROE % | — | — |
| Debt / equity | — | — |
| FCF yield % | 3.7 | -7.9 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.99 |
| RSI (14) | 59.7 | 27.0 |
| Technical rating |